VERTEPORFIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (VAM): An Open-label Multicenter Photodynamic Therapy Study of 4,435 Patients
Explore this paper's citation graph
Summary
The therapy associated with a low incidence of adverse events when expanded access was provided in a large, open-label, multicenter study, including aLow incidence of reported photosensitivity reactions despite a short photosensitivity protection period (24 hours) following verteporfin administration.
- Type
- article
- Published
- 2004-08-01
- Cited by
- 38
- References
- 10
- OpenAlex
- https://openalex.org/W2407272824
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:9408867
Keywords
Verteporfin, Macular degeneration, Medicine, Choroidal neovascularization, Ophthalmology
References
- Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
- Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
- Verteporfin in Photodynamic Therapy (VIP) Study group.
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2.
- Neutrophil margination as a possible mechanism for verteporfin infusion-associated pain.
- Verteporfin infusion-associated pain.
- Treatment of Age-Related Macular Degeneration
- Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.
- Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
- Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5
Cited by
- Macular degeneration: a disease searching for a cure.
- [Evaluation of the macular function by focal electroretinography and by fluorescein angiography in patients with neovascular age-related macular degeneration submitted to verteporfin photodynamic therapy].
- Photodynamic therapy with verteporfin in age‐related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties
- What's new in ophthalmic surgery.
- Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
- A phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration.
- Comparative Assessment of Photodynamic Therapy for Typical Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A Multicenter Study in Hyogo Prefecture, Japan
- Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.
- HEMORRHAGIC COMPLICATIONS AFTER PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
- NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes
- Anaphylactoid reaction after verteporfin therapy.
- Ferritin Nanocages To Encapsulate and Deliver Photosensitizers for Efficient Photodynamic Therapy against Cancer
- Transcutaneous Electrical Retinal Stimulation Therapy for Age-Related Macular Degeneration
- Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density
- Type 1 phototherapeutic agents, part I: preparation and cancer cell viability studies of novel photolabile sulfenamides.
- Preclinical Comparison of mTHPC and Verteporfin for Intracavitary Photodynamic Therapy of Malignant Pleural Mesothelioma
- Photodynamic Therapy and Combination Treatments
- 12-MONTH RETROSPECTIVE STUDY AND REVIEW OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION
- A Preliminary Benefit-Risk Assessment of Verteporfin in Age-Related Macular Degeneration
- Verteporfin
Related papers
- Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
- Photodynamic Therapy in Retinal Angiomatous Proliferation Stage I
- Modified Verteporfin Photodynamic Therapy (PDT), PDT Combined With Angiostatin In Vitro and In Vivo
- No-Dose Photodynamic Therapy Against half-dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
- Infrared Imaging of Classic Choroidal Neovascularisation Treated with Verteporfin Photodynamic Therapy (PDT)
- Verteporfin Therapy with Delayed Light Application for the Treatment of Occult Choroidal Neovascularization (CNV) in Age-Related Macular Degeneration (AMD)
- Efficacy of photodynamic therapy with verteporfin combined with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration
- Photosensitizers and Photodynamic Therapy: Verteporfin.
- CASE SERIES OUTCOMES AT 1 WEEK FOLLOWING VERTEPORFIN PHOTODYNAMIC THERAPY
- Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.